Cargando…

Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat

BACKGROUND: A decreased prostatic blood flow could be one of the risk factors for benign prostatic hyperplasia/benign prostatic enlargement. The spontaneously hypertensive rat (SHR) shows a chronic prostatic ischemia and hyperplastic morphological abnormalities in the ventral prostate. The effect of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimizu, Shogo, Shimizu, Takahiro, Tsounapi, Panagiota, Higashi, Youichirou, Martin, Darryl T., Nakamura, Kumiko, Honda, Masashi, Inoue, Keiji, Saito, Motoaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550428/ https://www.ncbi.nlm.nih.gov/pubmed/26308715 http://dx.doi.org/10.1371/journal.pone.0133798

Ejemplares similares

Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH
por: Saito, Motoaki, et al.
Publicado: (2014)

Angiotensin II centrally induces frequent detrusor contractility of the bladder by acting on brain angiotensin II type 1 receptors in rats
por: Kawamoto, Bunya, et al.
Publicado: (2016)

Protective Role of Glutathione in the Hippocampus after Brain Ischemia
por: Higashi, Youichirou, et al.
Publicado: (2021)

Influence of extracellular zinc on M1 microglial activation
por: Higashi, Youichirou, et al.
Publicado: (2017)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009)

Angiotensin II acting on brain AT(1) receptors induces adrenaline secretion and pressor responses in the rat
por: Nakamura, Kumiko, et al.
Publicado: (2014)

Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
por: Yoshida, Masaki, et al.
Publicado: (2011)

Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
por: Sakata, Koichi, et al.
Publicado: (2012)

Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
por: Tanaka, Nobumichi, et al.
Publicado: (2014)

Long-Term Efficacy, Safety, and Tolerability of Modified Intravesical Oxybutynin Chloride for Neurogenic Bladder in Children
por: Honda, Masashi, et al.
Publicado: (2019)

Potential role of ghrelin on the micturition reflex in rats
por: Honda, Masashi, et al.
Publicado: (2021)

Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability
por: Cho, Hee Ju, et al.
Publicado: (2014)

Effects of intravesical administration of sensory neuron-specific receptor agonist on voiding function in rats with cyclophosphamide-induced cystitis
por: Honda, Masashi, et al.
Publicado: (2019)

Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial
por: Pande, Satabdi, et al.
Publicado: (2014)

The Effectiveness of Silodosin for Nocturnal Polyuria in Elderly Men With Benign Prostatic Hyperplasia: A Multicenter Study
por: Kim, Young Won, et al.
Publicado: (2015)

Efficacy and Safety of the Selective α(1A)-Adrenoceptor Blocker Silodosin for Severe Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Prospective, Single-Open-Label, Multicenter Study in Korea
por: Moon, Ki Hak, et al.
Publicado: (2014)

Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study
por: Takahashi, Hiroshi, et al.
Publicado: (2019)

Impact of antioxidants on seminal vesicles function and fertilizing potential in diabetic rats
por: Tsounapi, Panagiota, et al.
Publicado: (2017)

Focus on Silodosin: Pros and Cons of Uroselectivity
por: Califano, Gianluigi, et al.
Publicado: (2020)

A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia
por: Manjunatha, R., et al.
Publicado: (2016)

Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study
por: Hagiwara, Kazuhisa, et al.
Publicado: (2016)

Elevated Cell Invasion in a Tumor Sphere Culture of RSV-M Mouse Glioma Cells
por: NONAKA, Motonobu, et al.
Publicado: (2015)

Intravesical prostatic protrusion may affect early postoperative continence undergoing robot-assisted radical prostatectomy
por: Hikita, Katsuya, et al.
Publicado: (2020)

A Suspected Case of Silodosin-Induced Erythroderma
por: Liu, Annie, et al.
Publicado: (2015)

Silodosin-associated intraoperative floppy iris syndrome
por: Chatterjee, Samrat, et al.
Publicado: (2017)

Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone
por: Boeri, Luca, et al.
Publicado: (2017)

Comparing tamsulosin, silodosin versus silodosin plus tadalafil as medical expulsive therapy for lower ureteric stones: A randomised trial
por: Rahman, Md Jawaid, et al.
Publicado: (2017)

Search for new α1a-adrenoceptor-selective antagonist for treating lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Khurana, Naval, et al.
Publicado: (2007)

Five-mer peptides prevent short-term spatial memory deficits in Aβ25-35-induced Alzheimer’s model mouse by suppressing Aβ25-35 aggregation and resolving its aggregate form
por: Nakamura, Rina, et al.
Publicado: (2023)

Repurposing of α1-Adrenoceptor Antagonists: Impact in Renal Cancer
por: Mihalopoulos, Meredith, et al.
Publicado: (2020)

Evaluation of Silodosin and Pelvic Floor Muscle Training in Men with Benign Prostatic Hyperplasia and Overactive Bladder (Silodosing) Study Protocol (Spirit Compliant)
por: Hagovska, Magdalena, et al.
Publicado: (2021)

β(1) Adrenoceptor antagonistic effects of the supposedly selective β(2) adrenoceptor antagonist ICI 118,551 on the positive inotropic effect of adrenaline in murine hearts
por: Pecha, Simon, et al.
Publicado: (2015)

Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing
por: Suzuki, Shuhei, et al.
Publicado: (2020)

The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers
por: Batty, Mallory, et al.
Publicado: (2016)

Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies
por: Gittelman, Marc C, et al.
Publicado: (2010)

The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
por: Tanaka, Yoshinori, et al.
Publicado: (2017)

The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptors
por: Proudman, Richard G.W., et al.
Publicado: (2022)

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review
por: Jindan, Luo, et al.
Publicado: (2022)

Exploring a Bioequivalence Failure for Silodosin Products Due to Disintegrant Excipients
por: González-Álvarez, Isabel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2sh58ibpmiu870khg4gpn09v44